This website is intended for residents of the U.S. interested in achondroplasia or VOXZOGO
Search

Begin as early as birth with VOXZOGO

Sophie, 9 months old, on VOXZOGO since 3 months old

The first and only treatment FDA approved from birth until growth plates close for children with achondroplasia

Discover the impact of VOXZOGO—the longest-studied medicine for children with achondroplasia.

VOXZOGO supports bone growth from birth.

Why VOXZOGO

Treatment with ongoing results
in achondroplasia.

Clinical Trial Results

Carefully evaluated safety in infants and children over time.

Understanding Safety

A routine that can fit
into your daily life.

How to Give VOXZOGO
Play

“We decided to start Sophie on VOXZOGO at 3 months old after learning that the most significant growth period for children is between birth and 2 years old.”

– Amanda, Sophie’s mom

Attend an educational event

Experienced doctors and caregivers share their insights about achondroplasia and VOXZOGO.

Sign Up
A caregiver's guide to VOXZOGO—the first and only FDA-approved treatment from birth for children with achondroplasia

A caregiver’s guide
to VOXZOGO

Learn more about the first and only treatment FDA approved from birth until growth plates close for children with achondroplasia.

Download

Common questions about VOXZOGO

How does VOXZOGO work?

VOXZOGO targets the cause of inhibited bone growth throughout the body. VOXZOGO helps to improve the imbalance of cell signals and promotes bone growth.

Can my newborn start on VOXZOGO?

VOXZOGO is FDA approved for children with achondroplasia and open growth plates as early as birth.

What are the clinical trial results of VOXZOGO?

VOXZOGO was studied in a clinical trial of children with achondroplasia to assess the impact it had on linear growth over 1 year. After 1 year, children grew faster on VOXZOGO than without treatment.

Review the data of the clinical trial and the ongoing results of VOXZOGO.

How long has the safety of VOXZOGO been studied?

VOXZOGO has been carefully evaluated in infants and children with achondroplasia over 4+ years.

What does the needle for VOXZOGO look like?

VOXZOGO is given with a short, thin needle—smaller than the one used for most vaccinations. Your child’s doctor will train you on how to give VOXZOGO and your BioMarin Clinical Coordinator will be available to reinforce training.

Learn more about giving your child VOXZOGO and how to fit this routine into your daily life.

How can I get my infant or child started on VOXZOGO?

Talk with your child’s doctor about beginning VOXZOGO as early as possible to help give them the most time possible to benefit from treatment. You can also connect with a local BioMarin representative to learn more about getting started.

Looking for more information about VOXZOGO?

Your local BioMarin representative can help you find answers.

Connect now

Connect With a Rep

IMPORTANT SAFETY INFORMATION

What is the most important safety information about VOXZOGO?

  • VOXZOGO may cause serious side effects including a temporary decrease in blood pressure in some patients. To reduce the risk of a decrease in blood pressure and associated symptoms (dizziness, feeling tired, or nausea), patients should eat a meal and drink 8 to 10 ounces of fluid within 1 hour before receiving VOXZOGO.

What are the most common side effects of VOXZOGO?

  • The most common side effects of VOXZOGO include injection site reactions (including redness, itching, swelling, bruising, rash, hives, and injection site pain), high levels of blood alkaline phosphatase shown in blood tests, vomiting, joint pain, decreased blood pressure, and stomach ache. These are not all the possible side effects of VOXZOGO. Ask your healthcare provider for medical advice about side effects, and about any side effects that bother the patient or that do not go away.

How is VOXZOGO taken?

  • VOXZOGO is taken daily as an injection given under the skin, administered by a caregiver after a healthcare provider determines the caregiver is able to administer VOXZOGO. Do not try to inject VOXZOGO until you have been shown the right way by your healthcare provider. VOXZOGO is supplied with Instructions for Use that describe the steps for preparing, injecting, and disposing VOXZOGO. Caregivers should review the Instructions for Use for guidance and any time they receive a refill of VOXZOGO in case any changes have been made.
  • Inject VOXZOGO 1 time every day, at about the same time each day. If a dose of VOXZOGO is missed, it can be given within 12 hours from the missed dose. After 12 hours, skip the missed dose and administer the next daily dose as usual.
  • The dose of VOXZOGO is based on body weight. Your healthcare provider will adjust the dose based on changes in weight following regular check-ups.
  • Your healthcare provider will monitor the patient’s growth and tell you when to stop taking VOXZOGO if they determine the patient is no longer able to grow. Stop administering VOXZOGO if instructed by your healthcare provider.

What should you tell the doctor before or during taking VOXZOGO?

  • Tell your doctor about all of the patient’s medical conditions including
    • If the patient has heart disease (cardiac or vascular disease), or if the patient is on blood pressure medicine (anti-hypertensive medicine).
    • If the patient has kidney problems or renal impairment.
    • If the patient is pregnant or plans to become pregnant. It is not known if VOXZOGO will harm the unborn baby.
    • If the patient is breastfeeding or plans to breastfeed. It is not known if VOXZOGO passes into breast milk.
  • Tell your doctor about all of the medicines the patient takes, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to BioMarin at 1-866-906-6100. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see additional safety information in the full Prescribing Information and Patient Information.

What is VOXZOGO used for?

  • VOXZOGO is a prescription medicine used to increase linear growth in children with achondroplasia and open growth plates (epiphyses).
  • VOXZOGO is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.